Insert Therapeutics

As a result, it will be up to the new court to rule on CSHL's allegations that the law firm Ropes & Gray mishandled certain RNAi-related intellectual property stemming from the work of Greg Hannon and maintained improper business relationships with RNAi drug developers.

The new allegations are an attempt by CSHL to delay a ruling on the dismissal of the lawsuit so that it can review certain RNAi companies' confidential materials, the law firm alleged.

CSHL specifically names Arrowhead Research subsidiaries Calando Pharmaceuticals and Insert Therapeutics, which were merged into one firm under the Calando name in 2008, and RXi Pharmaceuticals.

During a conference call held this week to discuss Arrowhead Research's fiscal first-quarter financial results, President and CEO Christopher Anzalone said that the company was in a position to stay afloat for at least the next nine months.

Researchers have developed a way to quickly edit white blood cells, according to the New York Times.

In a commentary at eLife, Brandeis University's Eve Marder calls on researchers to value and pursue truth.

In Science this week: rice gene enables plants to grow quickly in times of flooding, and more.

Education-linked genetic variants could also predict a small portion of a person's social mobility, Newsweek reports.